CompanyTRAXNasdaqSan Diego, CA

First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics develops antibody therapies targeting immune pathways in autoimmune and inflammatory diseases.

SEC EDGAR ClinicalTrials.gov firsttracksbio.com

8-KSep 21Latest SEC filing, period to Sep 21

Aug 12Latest story

August 2026

First Tracks reports Q2 2026 results, ANB033 gets FDA Fast Track in celiac disease

Aug 12Quarterly updateFirst Tracks Biotherapeutics, Inc.